Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05194475 · ClinicalTrials.gov registry record · NA

Metabolic Effects of a Thermogenic Ready-to-drink Beverage

A NA study of Metabolism and Metabolic Rate, sponsored by Texas Tech University.

Completed
Registry status
NA
Development phase
28
Enrollment target
1
Study location

NCT05194475: Completed NA study of Metabolism and Metabolic Rate, sponsored by Texas Tech University.

NCT05194475 is a NA study of Metabolism and Metabolic Rate that has completed, run by Texas Tech University. The registered enrollment target is 28 participants, below the 13,264-participant average among 19 other Metabolism trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05194475, a NA study of Metabolism and Metabolic Rate, has completed, sponsored by Texas Tech University.

COMPLETED
Registry status
NA
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

This study is a randomized, double-blind, placebo-controlled crossover trial examining the metabolic effects of a novel ready-to-drink (RTD) beverage. Healthy adult males and females will be recruited for participation. Each participant will complete two conditions in random order: 1) RTD thermogenic beverage ; and 2) placebo (consisting of the flavoring of the thermogenic beverage without the active ingredients). In each condition, metabolism (resting metabolic rate), hemodynamic (heart rate and blood pressure), and subjective (ratings of energy, focus, concentration, alertness, and mood) assessments will be completed at baseline, 30 minutes after beverage consumption, and 30 minutes after the second round of assessments.

Primary Outcome

Resting metabolic rate from indirect calorimetry expressed as kilocalories expended per unit time (e.g., kcal/min).

Interventions

  • OTHER Thermogenic Ready-to-drink Beverage
  • OTHER Placebo Ready-to-drink Beverage

Study Locations (1)

Texas

  • Department of Kinesiology & Sport Management - Lubbock

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2022-01-18
Est. Completion 2022-05-06
Phase NA
Texas Tech University

69 total trials

What the finished NCT05194475 record still lists

NCT05194475 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 13,264-participant average among 19 other Metabolism trials with a reported enrollment target (100% lower).

The record links to 2 conditions, with Metabolism appearing as the primary indexed condition, and to 2 interventions - of which Thermogenic Ready-to-drink Beverage is the first listed.

NCT05194475 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05194475 about?

NCT05194475 is a clinical study titled "Metabolic Effects of a Thermogenic Ready-to-drink Beverage". This study is a randomized, double-blind, placebo-controlled crossover trial examining the metabolic effects of a novel ready-to-drink (RTD) beverage. Healthy adult males and females will be recruited for participation. Each participant will complete two conditions in random order: 1) RTD thermogeni...

What is the current status of trial NCT05194475?

This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2022-01-18. Estimated completion is 2022-05-06.

What conditions does trial NCT05194475 study?

This clinical trial studies the following conditions: Metabolism, Metabolic Rate.

What interventions are being tested in trial NCT05194475?

The interventions under investigation include: Thermogenic Ready-to-drink Beverage (OTHER), Placebo Ready-to-drink Beverage (OTHER).

Who is sponsoring clinical trial NCT05194475?

This trial is sponsored by Texas Tech University, which has 69 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05194475 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metabolism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05194475's enrollment target sits among peer trials

28 11th of 19 higher than 9 of 19 other Metabolism trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metabolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05194475, the US trial registry maintained by the National Library of Medicine. NCT05194475 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.